Market Research

Hepatitis E Diagnostic Tests Market Size, Share & Trends Analysis Report By Type (ELISA HEV IgM Test, Rapid Diagnostics Test), By End Use (Hospitals, Blood Banks), By Region, And Segment Forecasts, 2024 - 2030

Best Price Guarantee Length Publisher Published Date SKU
from $5,950 120 Pages Grand View Research July, 2024 GV19065892
Best Price Guarantee
Price from $5,950
Length 120 Pages
Publisher Grand View Research
Published Date July, 2024
SKU GV19065892

Hepatitis E Diagnostic Tests Market Size, Share & Trends Analysis Report By Type (ELISA HEV IgM Test, Rapid Diagnostics Test), By End Use (Hospitals, Blood Banks), By Region, And Segment Forecasts, 2024 - 2030


Hepatitis E Diagnostic Tests Market Trends

The global hepatitis E diagnostic tests market size was estimated at USD 54.75 million in 2023 and is projected to grow at a CAGR of 4.77% from 2024 to 2030. This growth is attributed to the rising incidences of hepatitis E, increased awareness about the need for early detection, and advancement in diagnostic technologies. According to the World Health Organization (WHO), approximately 20 million people worldwide are infected with the hepatitis E virus (HEV) each year, leading to approximately 3.3 million cases of symptomatic hepatitis E.

The global market has witnessed significant technological advancements in recent years, driving improvements in the accuracy, efficiency, and accessibility of diagnostic solutions. For Instance, in June 2021, DiaSorin introduced the fully automated high-throughput CLIA solution for diagnosis, available in countries that accept the CE market. DiaSorin's new offering represents a significant advancement in hepatitis E diagnostics. The fully automated CLIA (Chemiluminescence Immunoassay) platform enables high-throughput testing, allowing healthcare providers to screen and diagnose many patients efficiently. This is particularly important in regions with a high prevalence of hepatitis E, where the ability to identify infected individuals rapidly is crucial for effective disease management and prevention. The availability of such advanced diagnostic platforms aligns with the growing demand for accurate and efficient hepatitis E testing solutions.

Efforts to raise awareness among healthcare providers, at-risk populations, and the general public are also significant in driving market growth. Greater awareness about the risks and consequences of hepatitis E, such as the higher mortality rates in pregnant women, is fueling the demand for accurate diagnostic tests. The inclusion of hepatitis E tests in the WHO's 2023 Essential Diagnostics List reflects the increasing global recognition of the importance of early detection and management of hepatitis E.

Governments and healthcare systems recognize the need for improved surveillance and outbreak management, leading to increased procurement of HEV diagnostic kits. Patients and clinicians also seek better access to hepatitis E tests to enable early diagnosis and timely treatment, further boosting market growth. For instance, the Government of India comprehensive National Viral Hepatitis Control Program aims to address the burden of all forms of viral hepatitis, including Hepatitis E, through a multi-pronged approach focused on prevention, diagnosis, and treatment. The program involves significant government funding and a decentralized implementation strategy to strengthen the healthcare system's capacity to manage viral hepatitis effectively.

The increasing healthcare expenditure, particularly in emerging markets, is supporting the market growth. The growing emphasis on early detection and effective disease management is driving the demand for diagnostic tests. As awareness about the disease increases, there is a greater focus on implementing preventive measures such as personal hygiene, safe water sources, proper sanitation, and food safety to curb the spread of the virus.

Global Hepatitis E Diagnostic Tests Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2030. For this study, Grand View Research has segmented the global hepatitis E diagnostic tests market report based on type, end use, and region.
  • Type Outlook (Revenue, USD Million, 2018 - 2030)
  • ELISA HEV IgM Test
  • ELISA HEV IgG Test
  • Rapid Diagnostics Test
  • Polymerase Chain Reaction (PCR)
  • End Use Outlook (Revenue, USD Million, 2018 - 2030)
  • Hospital
  • Diagnostics Laboratories
  • Blood Banks
  • Other End User
  • Regional Outlook (Revenue in USD Million, 2018 - 2030)
  • North America
  • U.S.
  • Canada
  • Mexico
  • Europe
  • UK
  • Germany
  • France
  • Italy
  • Spain
  • Denmark
  • Sweden
  • Norway
  • Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Thailand
  • Latin America
  • Brazil
  • Argentina
  • Middle East and Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait
Please note The report will be delivered in 2-3 business days upon order notification.


Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.2. Segment Definitions
1.2.1. Type
1.2.2. End Use
1.2.3. Regional scope
1.2.4. Estimates and forecasts timeline
1.3. Research Methodology
1.4. Information Procurement
1.4.1. Purchased database
1.4.2. GVR’s internal database
1.4.3. Secondary sources
1.4.4. Primary research
1.4.5. Details of primary research
1.4.5.1. Data for primary interviews in North America
1.4.5.2. Data for primary interviews in Europe
1.4.5.3. Data for primary interviews in Asia Pacific
1.4.5.4. Data for primary interviews in Latin America
1.4.5.5. Data for Primary interviews in MEA
1.5. Information or Data Analysis
1.5.1. Data analysis models
1.6. Market Formulation & Validation
1.7. Model Details
1.7.1. Commodity flow analysis (Model 1)
1.7.2. Approach 1: Commodity flow approach
1.7.3. Volume price analysis (Model 2)
1.7.4. Approach 2: Volume price analysis
1.8. List of Secondary Sources
1.9. List of Primary Sources
1.10. Objectives
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.2.1. Test outlook
2.2.2. End Use outlook
2.2.3. Regional outlook
2.3. Competitive Insights
Chapter 3. Hepatitis E Diagnostic Tests Market Variables, Trends & Scope
3.1. Market Lineage Outlook
3.1.1. Parent market outlook
3.1.2. Related/ancillary market outlook
3.2. Market Dynamics
3.2.1. Market driver analysis
3.2.1.1. Rising incidences of hepatitis E
3.2.1.2. Technological advancements
3.2.1.3. Efforts to raise awareness
3.2.2. Market restraint analysis
3.2.2.1. Lack of awareness and access to Hepatitis E testing in developing regions
3.3. Hepatitis E Diagnostic Tests Market Analysis Tools
3.3.1. Industry Analysis - Porter’s
3.3.1.1. Supplier power
3.3.1.2. Buyer power
3.3.1.3. Substitution threat
3.3.1.4. Threat of new entrant
3.3.1.5. Competitive rivalry
3.3.2. PESTEL Analysis
3.3.2.1. Political landscape
3.3.2.2. Technological landscape
3.3.2.3. Economic landscape
3.3.3. Pipeline Analysis
Chapter 4. Hepatitis E Diagnostic Tests Market: Treatment Estimates & Trend Analysis
4.1. Global Hepatitis E Diagnostic Tests Market: Type Dashboard
4.2. Global Hepatitis E Diagnostic Tests Market: Type Analysis
4.3. Global Hepatitis E Diagnostic Tests Market by Type, Revenue
4.4. ELISA HEV IgM Test
4.4.1. ELISA HEV IgM Test market estimates and forecasts, 2018 to 2030 (USD Million)
4.5. ELISA HEV IgG Test
4.5.1. ELISA HEV IgG Test market estimates and forecasts, 2018 to 2030 (USD Million)
4.6. Rapid Diagnostics Test
4.6.1. Rapid Diagnostics Test market estimates and forecasts, 2018 to 2030 (USD Million)
4.7. Polymerase Chain Reaction (PCR)
4.7.1. Polymerase Chain Reaction (PCR) market estimates and forecasts, 2018 to 2030 (USD Million)
Chapter 5. Hepatitis E Diagnostic Tests Market: End Use Estimates & Trend Analysis
5.1. Global Hepatitis E Diagnostic Tests Market: End Use Dashboard
5.2. Global Hepatitis E Diagnostic Tests Market: End Use Movement Analysis
5.3. Global Hepatitis E Diagnostic Tests Market Estimates and Forecasts, By End Use, Revenue (USD Million)
5.4. Hospital
5.4.1. Hospital market estimates and forecasts, 2018 to 2030 (USD Million)
5.5. Diagnostics Laboratories
5.5.1. Diagnostic Laboratories market estimates and forecasts, 2018 to 2030 (USD Million)
5.6. Blood Banks
5.6.1. Blood Banks market estimates and forecasts, 2018 to 2030 (USD Million)
5.7. Other End Use
5.7.1. Other End Use market estimates and forecasts, 2018 to 2030 (USD Million)
Chapter 6. Hepatitis E Diagnostic Tests Market: Regional Estimates & Trend Analysis by Type and End Use
6.1. Regional Dashboard
6.2. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
6.3. North America
6.3.1. U.S.
6.3.1.1. Key country dynamics
6.3.1.2. Regulatory framework/ reimbursement structure
6.3.1.3. Competitive scenario
6.3.1.4. U.S. market estimates and forecasts, 2018 to 2030 (USD Million)
6.3.2. Canada
6.3.2.1. Key country dynamics
6.3.2.2. Regulatory framework/ reimbursement structure
6.3.2.3. Competitive scenario
6.3.2.4. Canada market estimates and forecasts, 2018 to 2030 (USD Million)
6.3.3. Mexico
6.3.3.1. Key country dynamics
6.3.3.2. Regulatory framework/ reimbursement structure
6.3.3.3. Competitive scenario
6.3.3.4. Mexico market estimates and forecasts, 2018 to 2030 (USD Million)
6.4. Europe
6.4.1. UK
6.4.1.1. Key country dynamics
6.4.1.2. Regulatory framework/ reimbursement structure
6.4.1.3. Competitive scenario
6.4.1.4. UK market estimates and forecasts, 2018 to 2030 (USD Million)
6.4.2. Germany
6.4.2.1. Key country dynamics
6.4.2.2. Regulatory framework/ reimbursement structure
6.4.2.3. Competitive scenario
6.4.2.4. Germany market estimates and forecasts, 2018 to 2030 (USD Million)
6.4.3. France
6.4.3.1. Key country dynamics
6.4.3.2. Regulatory framework/ reimbursement structure
6.4.3.3. Competitive scenario
6.4.3.4. France market estimates and forecasts, 2018 to 2030 (USD Million)
6.4.4. Italy
6.4.4.1. Key country dynamics
6.4.4.2. Regulatory framework/ reimbursement structure
6.4.4.3. Competitive scenario
6.4.4.4. Italy market estimates and forecasts, 2018 to 2030 (USD Million)
6.4.5. Spain
6.4.5.1. Key country dynamics
6.4.5.2. Regulatory framework/ reimbursement structure
6.4.5.3. Competitive scenario
6.4.5.4. Spain market estimates and forecasts, 2018 to 2030 (USD Million)
6.4.6. Norway
6.4.6.1. Key country dynamics
6.4.6.2. Regulatory framework/ reimbursement structure
6.4.6.3. Competitive scenario
6.4.6.4. Norway market estimates and forecasts, 2018 to 2030 (USD Million)
6.4.7. Sweden
6.4.7.1. Key country dynamics
6.4.7.2. Regulatory framework/ reimbursement structure
6.4.7.3. Competitive scenario
6.4.7.4. Sweden market estimates and forecasts, 2018 to 2030 (USD Million)
6.4.8. Denmark
6.4.8.1. Key country dynamics
6.4.8.2. Regulatory framework/ reimbursement structure
6.4.8.3. Competitive scenario
6.4.8.4. Denmark market estimates and forecasts, 2018 to 2030 (USD Million)
6.5. Asia Pacific
6.5.1. Japan
6.5.1.1. Key country dynamics
6.5.1.2. Regulatory framework/ reimbursement structure
6.5.1.3. Competitive scenario
6.5.1.4. Japan market estimates and forecasts, 2018 to 2030 (USD Million)
6.5.2. China
6.5.2.1. Key country dynamics
6.5.2.2. Regulatory framework/ reimbursement structure
6.5.2.3. Competitive scenario
6.5.2.4. China market estimates and forecasts, 2018 to 2030 (USD Million)
6.5.3. India
6.5.3.1. Key country dynamics
6.5.3.2. Regulatory framework/ reimbursement structure
6.5.3.3. Competitive scenario
6.5.3.4. India market estimates and forecasts, 2018 to 2030 (USD Million)
6.5.4. Australia
6.5.4.1. Key country dynamics
6.5.4.2. Regulatory framework/ reimbursement structure
6.5.4.3. Competitive scenario
6.5.4.4. Australia market estimates and forecasts, 2018 to 2030 (USD Million)
6.5.5. South Korea
6.5.5.1. Key country dynamics
6.5.5.2. Regulatory framework/ reimbursement structure
6.5.5.3. Competitive scenario
6.5.5.4. South Korea market estimates and forecasts, 2018 to 2030 (USD Million)
6.5.6. Thailand
6.5.6.1. Key country dynamics
6.5.6.2. Regulatory framework/ reimbursement structure
6.5.6.3. Competitive scenario
6.5.6.4. Thailand market estimates and forecasts, 2018 to 2030 (USD Million)
6.6. Latin America
6.6.1. Brazil
6.6.1.1. Key country dynamics
6.6.1.2. Regulatory framework/ reimbursement structure
6.6.1.3. Competitive scenario
6.6.1.4. Brazil market estimates and forecasts, 2018 to 2030 (USD Million)
6.6.2. Argentina
6.6.2.1. Key country dynamics
6.6.2.2. Regulatory framework/ reimbursement structure
6.6.2.3. Competitive scenario
6.6.2.4. Argentina market estimates and forecasts, 2018 to 2030 (USD Million)
6.7. MEA
6.7.1. South Africa
6.7.1.1. Key country dynamics
6.7.1.2. Regulatory framework/ reimbursement structure
6.7.1.3. Competitive scenario
6.7.1.4. South Africa market estimates and forecasts, 2018 to 2030 (USD Million)
6.7.2. Saudi Arabia
6.7.2.1. Key country dynamics
6.7.2.2. Regulatory framework/ reimbursement structure
6.7.2.3. Competitive scenario
6.7.2.4. Saudi Arabia market estimates and forecasts, 2018 to 2030 (USD Million)
6.7.3. UAE
6.7.3.1. Key country dynamics
6.7.3.2. Regulatory framework/ reimbursement structure
6.7.3.3. Competitive scenario
6.7.3.4. UAE market estimates and forecasts, 2018 to 2030 (USD Million)
6.7.4. Kuwait
6.7.4.1. Key country dynamics
6.7.4.2. Regulatory framework/ reimbursement structure
6.7.4.3. Competitive scenario
6.7.4.4. Kuwait market estimates and forecasts, 2018 to 2030 (USD Million)
Chapter 7. Competitive Landscape
7.1. Company/Competition Categorization
7.2. Vendor Landscape
7.2.1. List of key distributors and channel partners
7.2.2. Key customers
7.2.3. Key company market share analysis, 2023
7.2.4. Wantai BioPharm
7.2.4.1. Company overview
7.2.4.2. Financial performance
7.2.4.3. Product benchmarking
7.2.4.4. Strategic initiatives
7.2.5. MP Biomedicals LLP
7.2.5.1. Company overview
7.2.5.2. Financial performance
7.2.5.3. Product benchmarking
7.2.5.4. Strategic initiatives
7.2.6. PerkinElmer, Inc
7.2.6.1. Company overview
7.2.6.2. Financial performance
7.2.6.3. Product benchmarking
7.2.6.4. Strategic initiatives
7.2.7. DIa.Pro diagnostic Bioprobes srl
7.2.7.1. Company overview
7.2.7.2. Financial performance
7.2.7.3. Product benchmarking
7.2.7.4. Strategic initiatives
7.2.8. ELITechGroup
7.2.8.1. Company overview
7.2.8.2. Financial performance
7.2.8.3. Product benchmarking
7.2.8.4. Strategic initiatives
7.2.9. Primerdesign Ltd
7.2.9.1. Company overview
7.2.9.2. Financial performance
7.2.9.3. Product benchmarking
7.2.9.4. Strategic initiatives
7.2.10. F.Hoffmann-La Roche Ltd
7.2.10.1. Company overview
7.2.10.2. Financial performance
7.2.10.3. Product benchmarking
7.2.10.4. Strategic initiatives
7.2.11. Mikrogen GmbH
7.2.11.1. Company overview
7.2.11.2. Financial performance
7.2.11.3. Product benchmarking
7.2.11.4. Strategic initiatives
7.2.12. Altona Diagnostics
7.2.12.1. Company overview
7.2.12.2. Financial performance
7.2.12.3. Product benchmarking
7.2.12.4. Strategic initiatives
7.2.13. Fortress Diagnostics
7.2.13.1. Company overview
7.2.13.2. Financial performance
7.2.13.3. Product benchmarking
7.2.13.4. Strategic initiatives

$5,950
$6,950
$8,950

Research Assistance

US: 800.298.5699
Int'l: +1.240.747.3093
Live help
Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Other tasks

Cookie Settings